Effect of a patient-centered decision app on TOLAC: An RCT

以患者为中心的决策应用程序对 TOLAC 的影响:随机对照试验

基本信息

项目摘要

DESCRIPTION (provided by applicant): Cesarean delivery (CD) accounts for one-third of all births in the US, representing an increase of approximately 50% in the last decade. Elective repeat CDs (ERCD) are a significant contributor to the rising cesarean rate, resulting from the combination of an increasing rate of primary CD and a decreasing rate of vaginal birth after cesarean (VBAC). A primary driver of the decreased frequency of VBAC is the decline in frequency with which eligible women elect a trial of labor after cesarean (TOLAC). The reasons for this decline are unclear; in particular, little is known about the extent to which patient preferences have contributed to this decrease. In addition, tools to help patients and providers engage in patient-preference driven, shared decision making regarding approach to delivery after cesarean are lacking. We propose to 1) identify patient preference drivers of delivery approach (TOLAC or ERCD) and mode (VBAC or CD) among 240 English- or Spanish-speaking TOLAC-eligible women; 2) use this data to create an innovative, personalized decision support mHealth app (Prior CD Decision App) that integrates values clarification exercises with a validated VBAC prediction tool; and 3) conduct a randomized trial of the Prior CD Decision App versus usual care among 1650 English- or Spanish-speaking women to assess its effect on TOLAC and VBAC rates and decision quality. Our hypotheses are that compared to women who receive only usual care, women who are randomized to use the Prior CD Decision App will be more likely to undergo TOLAC and have a VBAC and will experience less decisional conflict, be more knowledgeable about TOLAC and ERCD and experience more optimal shared decision making.
描述(由申请人提供):剖宫产(CD)占美国所有出生的三分之一,在过去十年中,大约增加了50%。选择性重复CD(ERCD)是剖宫产率上升的重要原因,这是由于原发性CD的增加和剖宫产后阴道出生率降低的组合所致(VBAC)。 VBAC频率降低的主要驱动力是符合条件的妇女选举剖宫产后(TOLAC)的劳动试验的频率下降。这种下降的原因尚不清楚。特别是,关于患者偏好导致这种减少的程度知之甚少。此外,缺乏剖宫产后,可以帮助患者和提供者从事以患者为驱动的,共同的决策。我们建议1)在240名英语或西班牙语符合TOLAC的女性中,确定患者偏好驱动力驱动方法(TOLAC或ERCD)和模式(VBAC或CD); 2)使用此数据创建创新的个性化决策支持MHealth应用程序(先前的CD决策应用程序),该应用程序将值澄清练习与经过验证的VBAC预测工具集成在一起; 3)在1650名说英语或西班牙语的妇女中,对先前的CD决策应用程序进行随机试验,以评估其对TOLAC和VBAC率和决策质量的影响。我们的假设是,与仅接受常规护理的妇女相比,随机使用先前的CD决策应用程序的女性更有可能进行TOLAC并具有VBAC,并且会经历较少的决策冲突,对Tolac和Ercd和ERCD和ERCD和经验更加最佳的共享决策更加了解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIRIAM KUPPERMANN其他文献

MIRIAM KUPPERMANN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIRIAM KUPPERMANN', 18)}}的其他基金

Promoting Shared Decision Making in Periviable Care: A randomized controlled trial of the Periviable GOALS Decision Support Tool
促进围产期护理中的共同决策:围产期目标决策支持工具的随机对照试验
  • 批准号:
    10491110
  • 财政年份:
    2021
  • 资助金额:
    $ 63.38万
  • 项目类别:
Promoting Shared Decision Making in Periviable Care: A randomized controlled trial of the Periviable GOALS Decision Support Tool
促进围产期护理中的共同决策:围产期目标决策支持工具的随机对照试验
  • 批准号:
    10366336
  • 财政年份:
    2021
  • 资助金额:
    $ 63.38万
  • 项目类别:
Promoting Shared Decision Making in Periviable Care: A randomized controlled trial of the Periviable GOALS Decision Support Tool
促进围产期护理中的共同决策:围产期目标决策支持工具的随机对照试验
  • 批准号:
    10693922
  • 财政年份:
    2021
  • 资助金额:
    $ 63.38万
  • 项目类别:
Understanding preferences regarding the offer of elective induction of labor to inform development of a decision support tool
了解有关选择性引产的偏好,为决策支持工具的开发提供信息
  • 批准号:
    10730074
  • 财政年份:
    2019
  • 资助金额:
    $ 63.38万
  • 项目类别:
Transdisciplinary Research Training to Reduce Disparities in Preterm Birth and Improve Maternal and Neonatal Outcomes
跨学科研究培训,以减少早产差异并改善孕产妇和新生儿结局
  • 批准号:
    9921460
  • 财政年份:
    2019
  • 资助金额:
    $ 63.38万
  • 项目类别:
Transdisciplinary Research Training to Reduce Disparities in Preterm Birth and Improve Maternal and Neonatal Outcomes
跨学科研究培训,以减少早产差异并改善孕产妇和新生儿结局
  • 批准号:
    10400055
  • 财政年份:
    2019
  • 资助金额:
    $ 63.38万
  • 项目类别:
Transdisciplinary Research Training to Reduce Disparities in Preterm Birth and Improve Maternal and Neonatal Outcomes
跨学科研究培训,以减少早产差异并改善孕产妇和新生儿结局
  • 批准号:
    10612870
  • 财政年份:
    2019
  • 资助金额:
    $ 63.38万
  • 项目类别:
Effect of a patient-centered decision app on TOLAC: An RCT
以患者为中心的决策应用程序对 TOLAC 的影响:随机对照试验
  • 批准号:
    8885864
  • 财政年份:
    2014
  • 资助金额:
    $ 63.38万
  • 项目类别:
Effect of a patient-centered decision app on TOLAC: An RCT
以患者为中心的决策应用程序对 TOLAC 的影响:随机对照试验
  • 批准号:
    8760269
  • 财政年份:
    2014
  • 资助金额:
    $ 63.38万
  • 项目类别:
Expanded Prenatal Testing Options and Informed Choice
扩大产前检测选项和知情选择
  • 批准号:
    7933158
  • 财政年份:
    2009
  • 资助金额:
    $ 63.38万
  • 项目类别:

相似海外基金

RP5 MPT Study
RP5 MPT 研究
  • 批准号:
    10595905
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
Trans/Forming Genomics: Guidance for Research Involving Transgender and Gender Diverse People
跨性别/形成基因组学:涉及跨性别和性别多样化人群的研究指南
  • 批准号:
    10728997
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
The Health of Aging Parents of Adult Children with Serious Conditions
患有严重疾病的成年子女的年迈父母的健康
  • 批准号:
    10660046
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
Craniofacial microsomia: Accelerating Research and Education (CARE)
颅面微小症:加速研究和教育 (CARE)
  • 批准号:
    10791256
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
Admin Suppl Gender-affirming estrogen therapy and breast cancer treatment outcome
行政补充性别肯定雌激素治疗和乳腺癌治疗结果
  • 批准号:
    10783533
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了